Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Revolution Medicines, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | -0.8100 | -1.826 | 50 | 50 | -47 | -206 | -48 | -50 | -145 | -50 | 12 | 93 |
| 2021 | -1.6200 | -2.503 | 42 | 28 | -108 | -168 | -108 | -161 | -242 | -168 | 21 | 27 |
| 2022 | -2.4700 | -3.292 | 29 | 27 | -179 | -186 | -187 | -179 | -195 | -187 | 30 | 51 |
| 2023 | -3.0800 | -3.478 | 35 | 12 | -248 | -519 | -249 | -183 | -267 | -192 | 40 | 23 |
| 2024 | -3.8600 | -3.388 | 11 | 0.60 | -436 | -383 | -477 | 0.60 | -487 | 0.60 | 72 | 1 |
| 2025 | - | -3.903 | - | 1 | - | -434 | - | -1 | - | -1 | - | 2 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |